Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by the targeting of anagen hair follicles by the host immune system, resulting in varying degrees of hair loss. While no therapies are approved for AA, topical / intralesional corticosteroids and topical or contact immunotherapy are commonly prescribed; JAK inhibitors (Pfizer’s Xeljanz, Eli Lilly’s Olumiant, Incyte’s Jakafi) may also be prescribed, albeit infrequently. As the AA current treatment landscape continues to evolve, this report offers insights from real-world claims data into prescribing trends in AA to help new players better understand current treatment practices in AA and to define the market niche for their emerging products.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
Markets covered: United States
Key drugs: Anthralin, minoxidil, corticosteroids, contact allergens, pimecrolimus, finasteride, methotrexate, cyclosporine A, Jakafi, Olumiant, tacrolimus (topical), Xeljanz